All In Biotech

NDA 018233 · Otsuka Icu Medcl

Sterile Water For Injection In Plastic Container

Sterile Water For Injection · N/A

Last checked: Nov 19, 2026Latest source record: Sep 5, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1980

Feb 18, 1980

Approved uses

1

Original approval plus efficacy supplements

Registered trials

555

138 Phase 3, 52 recruiting

FAERS reports

5,062

2,859 serious, 180 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 2, 2025.

INDICATIONS AND USAGE Sterile Water for Injection, USP is indicated for use only as a solvent or diluent vehicle for parenterally administered drugs or solutions and as a source of water for parenteral fluid replenishment after suitable additives are introduced. For intravenous administration, an osmolar concentration not less than two-fifths (0.4) of the normal osmolarity of the extracellular fluid (280 mOsmol/liter) is essential to avoid intravascular hemolysis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 18, 1980 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • STERILE WATER FOR INJECTION IN PLASTIC CONTAINER · STERILE WATER FOR INJECTION 100% · LIQUID, N/A · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Sterile Water For Injection" as an intervention, any sponsor and status, largest first.

All 555 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hereditary angioedema584
  • fatigue273
  • product dose omission issue265
  • nausea254
  • headache251
  • weight increased242
  • weight decreased239
  • pain228
  • inappropriate schedule of product administration217
  • pyrexia210
  • vomiting195
  • dyspnoea188

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200411
200512
20063
20078
20087
200910
201019
201111
201218
201318
2014112
2015272
2016222
2017204
2018583
2019337
2020209
2021335
2022546
2023420
2024614
2025691
2026400

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 13 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.